News

Axios on MSN13d
Vinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.
Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
Wellbeing Whisper on MSN20h
Why Most Americans Won't Need Covid Boosters Anymore and What It Means for You
We want to know more about what these products are doing,” said Dr. Vinay Prasad during a recent FDA livestreamed ...
BioPharma Dive13d
Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
Science-Based Medicine12dOpinion
Dr. Vinay Prasad is Now the Medical Establishment. It’s His Job to Run RCTs, and It’s Our Job to Call Him a Lying Piece of $#!& if He Fails.
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
BioSpace7d
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...
MedPage Today on MSN13dOpinion
Vinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?
The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
U.S. News & World Report14d
Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research. The division oversees vaccines and biologic ...
Bloomberg L.P.15d
FDA Names Vinay Prasad as New Head of Vaccines, Biologics
FDA Commissioner Marty Makary named Vinay Prasad, a hematologist oncologist and critic of the Covid-19 vaccine for children, as the next director of the Center for Biologics and Research.